Tourmaline Bio, Inc.
Tourmaline Bio, Inc. (TRML) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
trml · stock forecast · 10 analysts (3M) · FMP · updated Feb 3, 2026
Analyst Rating & Consensus
Based on 10 Wall Street analysts in the past 3 months
Hold
10 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$50.00
Consensus
$48.50
+1.1% upside
Low
$47.50
Median: $48 · Last Close: $47.98
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Consensus Target
$48.50
1.1% upside
High Target
$50
4.2%
Low Target
$47.5
-1.0%
Current Price
$47.98
as of today
Based on analyst price targets, the TRML stock price prediction for the next 12 months ranges from $47.5 to $50. The consensus TRML price forecast of $48.50 implies 1.1% upside from the current price of $47.98.
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $47.88 | ↓ 0.20% |
1-day model range: $47.87–$47.9. Peak: $47.9 (-0.20%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
NEUTRAL
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · TRML · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2025-09-15 | BMO Capital | Downgrade ↓ | Outperform→Market Perform |
| 2025-09-11 | Piper Sandler | Downgrade ↓ | Overweight→Neutral |
| 2025-09-10 | Truist Securities | Downgrade ↓ | Buy→Hold |
| 2025-09-10 | HC Wainwright & Co. | Downgrade ↓ | Buy→Neutral |
| 2025-09-10 | Chardan Capital | Downgrade ↓ | Buy→Neutral |
| 2025-09-10 | Guggenheim | Downgrade ↓ | Buy→Neutral |
| 2025-09-09 | LifeSci Capital | Downgrade ↓ | Outperform→Market Perform |
| 2025-09-09 | Jefferies | Downgrade ↓ | Buy→Hold |
| 2025-09-09 | Wedbush | Downgrade ↓ | Outperform→Neutral |
| 2025-08-14 | Chardan Capital | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Tourmaline Bio, Inc. (TRML) stock. Of the recent 24 rating actions, 0 were upgrades and 9 were downgrades. 10 analysts currently cover TRML.
Analyst Recommendation Trends
TRML analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$9M
↓ 48.6% YoY
Revenue Next Year
$9M
↑ 0.0% YoY
EPS This Year
$-3.70
EPS Next Year
$-4.04
↑ 9.0% YoY
EPS ForecastReported vs Estimated
Analysts forecast TRML EPS of $-3.70 for the current fiscal year, based on estimates from 7 analysts. The TRML revenue forecast is $9M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The TRML stock forecast is supported by two independent data sources: analyst consensus ratings from 10 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus TRML price target is $48.50 (+1.1% upside), with an analyst consensus of Hold.
The TRML short-term stock prediction for tomorrow is $47.88 (-0.20%).
Tourmaline Bio, Inc. trades on NASDAQ under the ticker TRML. The TRML stock outlook for 2027 is broadly mixed, supported by a Hold consensus among 10% of covering analysts.
Frequently asked questions
TRML forecast · 8 questionsAccording to 10 Wall Street analysts, the average 12-month TRML price target is $48.50, with a high forecast of $50.00 and a low of $47.50. The median price target is shown in the chart above when available. This implies +1.1% potential upside from the current price of $47.98.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.